Applying Evolving Targeted Therapy in Acute Myeloid Leukemia

To participate in this activity, please:

Acute Myeloid Leukemia (AML) is a biologically heterogeneous hematologic malignant neoplasm with a 5-year survival rate of 30%. Hematologist, Brian Jonas, MD, PhD, UC Davis Comprehensive Cancer, discusses standard induction, consolidation, and maintenance therapy, as well as factors to consider in individualizing intensive therapy in fit and unfit patients. Dr. Jonas presents safety and efficacy data for approved and emerging therapies that target BCL-2, FLT-3 ITD/TDK, CD33, CD47, IDH1/2, E-selectin, and SMO. Dr. Jonas utilizes case studies to share his insights in the treatment of patients with AML.

Course Credit:

0.75 ACPE Contact Hours
0.75 AMA PRA Category 1 CreditsTM
0.75 ANCC Contact Hours
0.75 CA-BRN Contact Hours
0.50 Pharmacology Hours

Dates:

Opens: 2023-09-30
Closes: 2024-09-30

Target Audience:

National audience of hematologist-oncologists, hematology advanced practitioners, hematology nurses, pathologists, emergency medicine physicians, pediatricians, primary care physicians, pharmacists, and other clinicians who diagnose or treat patients with AML.

This education activity is supported by an educational grant from AbbVie.

    Presenting Faculty

  • Brian Jonas, MD, PhD

    Professor of Medicine
    University of California, Davis
    Davis, California